Supplementary Figure S5 from Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung Cancer
Year: 2024
Type: supplementary-materials
Abstract: Supplementary Fig.S5 Associations between ctDNA molecular responses and tumor PD-L1 expression levels. (A) Association between PD-L1 expression and ctDNA molecular response in 24 patients with detectable ctDNA and evaluable PD-L1 expression, the subset of 8 patients who received chemo-immunotherapy combination treatments and (C) in 16 patients who received immune checkpoint monotherapy. P values were assessed using the Fisher’s exact test. (D-E) Survival analyses following the stratification of molecular response groups according to PD-L1 expression levels. Four molecular responders with cfTL clearance across any sampled timepoint and low/negative (<50%) PD-L1 expression had superior PFS compared to molecular responders with high (>50%) PD-L1 expression and molecular progressors (log-rank p = 0.006). Of these 4 patients, 3 received first line pembro-chemotherapy combination regimens and 1 patient received first line pembrolizumab monotherapy. Differences in OS were not significant between molecular response/PD-L1 expression groups (log-rank p = 0.135).
Authors: Joseph C. Murray, Lavanya Sivapalan, Karlijn Hummelink, Archana Balan, James R. White, Noushin Niknafs, Lamia Rhymee, Gavin Pereira, Nisha Rao, Benny Weksler, Nathan Bahary, Jillian Phallen, Alessandro Leal, David L. Bartlett, Kristen A. Marrone, Jarushka Naidoo, Akul Goel, Benjamin Levy, Samuel Rosner, Christine L. Hann, Susan C. Scott, Josephine Feliciano, Vincent K. Lam, David S. Ettinger, Qing Kay Li, Peter B. Illei, Kim Monkhorst, Robert B. Scharpf, Julie R. Brahmer, Victor E. Velculescu, Ali H. Zaidi, Patrick M. Forde, Valsamo Anagnostou
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4390950717